Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c02182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Meng Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, Collaborative Innovation Center For Guangxi Ethnic Medicine,…. Hauptthemen laut MEDLINE: Prodrugs, Reactive Oxygen Species, NF-kappa B, Antineoplastic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Huaiyin Institute of Technology, Jiangsu Key Laboratory of Regional Resource Exploitation and Medicinal Research, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Although cisplatin has been widely used for clinical purposes, its application is limited due to its obvious side effects. To mitigate the defects of cisplatin, here, six "multitarget prodrugs" were synthesized by linking cisplatin and NF-κB inhibitors. Notably, complex 9 demonstrated a 63-fold enhancement in the activity against A549/CDDP cells with lower toxicity toward normal LO2 cells compared to cisplatin. Additionally, complex 9 could effectively cause DNA damage, induce mitochondrial dysfunction, generate reactive oxygen species, and induce cell apoptosis through the mitochondrial pathway and ER stress. Remarkably, complex 9 effectively inhibited the NF-κB/MAPK signaling pathway and disrupted the PI3K/AKT signaling transduction. Importantly, complex 9 showed superior in vivo antitumor efficiency compared to cisplatin or the combination of cisplatin/4, without obvious systemic toxicity in A549 or A549/CDDP xenograft models. Our results demonstrated that the dual-acting mechanism endowed the complexes with high efficiency and low toxicity, which may represent an efficient strategy for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, Collaborative Innovation Center For Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal Uni…
- Jiangsu Key Laboratory of Regional Resource Exploitation and Medicinal Research, Huaiyin Institute of Technology, Huaian 223003, China.
- Guangxi Key Laboratory of Drug Discovery and Optimization, Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, School of Pharmacy, Guilin Medical University, Guilin 54…
ORCID-Profile: Hengshan Wang
Förderung
- Huaiyin Institute of Technology
- Jiangsu Key Laboratory of Regional Resource Exploitation and Medicinal Research
- China Postdoctoral Science Foundation
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Education
- National Natural Science Foundation of China
- Guangxi Key Laboratory of Drug Discovery and Optimization
Zitieren
APA
Wang, M., Li, G., Jiang, G., Cai, J., Liu, Z., Huang, R., Huang, X., & Wang, H. (2024). Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02182
Vancouver
Wang M, Li G, Jiang G, Cai J, Liu Z, Huang R, et al. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02182
BibTeX
@article{Wang2024,
author = {Wang, Meng and Li, Guimei and Jiang, Guiyang and Cai, Jinyuan and Liu, Zhikun and Huang, Rizhen and Huang, Xiaochao and Wang, Hengshan},
title = {Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02182}
}
EUVIMED